Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System

Open access
Lévy, Bernard I.·2004·Circulation

Abstract

T he renin-angiotensin system (RAS) plays a major role in regulating the cardiovascular system, and disorders of the RAS contribute largely to the pathophysiology of hypertension, renal diseases, and chronic heart failure.Two subtypes of angiotensin II (Ang II) receptors have been defined on the basis of their differential pharmacological and biochemical properties: Ang II type 1 receptors (AT 1 ), which are involved in most of the well-known physiological effects of Ang II, and Ang II type 2 receptors (AT 2 ), which have a less well-defined role but appear capable of counterbalancing some of the effects of AT 1 stimulation.The 2 receptors, both of which belong to the superfamily of G-protein-coupled receptors, are believed to have different signaling pathways and different functions. 1AT 1 transactivates growth pathways and mediates major Ang II effects such as vasoconstriction, increased cardiac contractility, renal tubular sodium reabsorption, cell proliferation, vascular and cardiac hypertrophy, inflammatory responses, and oxidative stress.AT 2 is believed to induce essentially opposite effects, including vasodilation and antigrowth and antihypertrophic effects, 1-3 and to play a significant role in blood pressure (BP) regulation. 4he 2 major pharmacological inhibitors of the RAS, which are now important elements in the treatment of hypertension and cardiovascular disease, are ACE inhibitors and angiotensin receptor blockers (ARBs).These 2 classes of drugs have different effects on the RAS: suppression of Ang II production by ACE inhibitors reduces activation of both Ang II receptor subtypes, whereas ARBs preferentially block AT 1 and leave AT 2 unopposed.Long-term administration of ARBs results in a several-fold increase in plasma Ang and thus a possible overstimulation of AT 2 .It is generally accepted that the effects of stimulation of AT 2 on the cardiovascular system are beneficial and that no harm would result from increased activation of these receptors; indeed, activation of AT 2 is believed to contribute to the benefits of blocking AT 1 .However, it was difficult to distinguish exactly which of the beneficial effects observed with ARBs arise from a fall in BP and which are due to activation of AT 2 .Recent work has attempted to unravel the receptor typedependent effects by using selective AT 2 antagonists or agonists or mice that have been genetically modified so that they either lack the gene coding for AT 2 or overexpress it.The results of this work often appear to be conflicting, but some of the evidence suggests that activation of AT 2 could, in certain contexts, exert growth stimulatory and proinflammatory effects that result in parallel, rather than opposite, effects to AT 1 stimulation.This article will attempt to briefly review the evidence on the cardiovascular role of AT 2 and to discuss possible implications of overstimulation of these receptors in long-term ARB therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000096609.73772.c5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 176

Metadata

Authors
Lévy, B. I.
Venue
Circulation
Published
2004-01-06
Volume
109
Issue
1
Pages
8-13
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2168720263
Cited by
176
References
1
FWCI
13.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System. https://app.cochat.ai/papers/10.1161/01.cir.0000096609.73772.c5
The paper
Lévy, B. I. (2004). Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System. Circulation. https://doi.org/10.1161/01.cir.0000096609.73772.c5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.